Trial reportJournal of pediatric hematology/oncology2014
Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.
Trial report in Journal of pediatric hematology/oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Participation in an occupational therapy referral program for children with retinoblastoma.Journal of pediatric rehabilitation medicine · 2016Trial
- Global, regional, and national burden and changing trends of hepatoblastoma and retinoblastoma from 1990 to 2021, and projections until 2050: findings from the Global Burden of Disease Study 2021.Translational pediatrics · 2026Article
- An exploratory study of sleep habits in school-aged survivors of retinoblastoma.Sleep medicine · 2023Article
- Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma.Children (Basel, Switzerland) · 2022Article
- High-Risk Histopathologic Features of Retinoblastoma Treated at a Tertiary Hospital in West Java, Indonesia.Ocular oncology and pathology · 2021Article
- Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion.BMC ophthalmology · 2021Article
- Retinoblastoma: Etiology, Modeling, and Treatment.Cancers · 2020Review
- Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.Journal of ophthalmology · 2020Article
- Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Treatment of Nonmetastatic Unilateral Retinoblastoma in Children.JAMA ophthalmology · 2018Article
- Immunohistochemical assay for neuron-specific enolase, synaptophysin, and RB-associated protein as a diagnostic aid in advanced retinoblastomas.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- A longitudinal investigation of parenting stress in caregivers of children with retinoblastoma.Pediatric blood & cancer · 2017Article
- Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities.Pediatric blood & cancer · 2016Article
- Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Mini reviews in medicinal chemistry · 2016Review
- Retinoblastoma.Nature reviews. Disease primers · 2015Review
- Management of retinoblastoma in children: current status.Paediatric drugs · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThere are no standardized diagnostic or treatment guidelines for patients with advanced unilateral retinoblastoma. MATERIALS AND
methodsPatients with advanced unilateral retinoblastoma were prospectively treated after enucleation using a risk-based protocol. Patients were assigned to low risk (LR), intermediate risk (IR), or high risk (HR) based on pathology. LR patients underwent observation. IR patients received 4 courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC). In the HR group, patients received 3 courses of VDC alternating with 3 courses of vincristine, carboplatin, and etoposide (VCE) and irradiation when indicated.
resultsFifty patients with advanced unilateral retinoblastoma were treated (LR, n=36; IR, n=7; HR, n=7). All eyes were Reese-Ellsworth group V. All bone scans (n=81), lumbar punctures (n=16), and bone marrow aspirates (n=16) were negative. Chemotherapy was well tolerated. Grades 3/4 hematologic toxicities were seen in all patients; grades 3/4 nonhematologic toxicities were seen in half the patients. Only one patient in the HR group received radiation therapy. All patients were alive at the time of analysis with no signs of disease recurrence. Median follow-up was 3.4 years (range, 0.8 to 6.4 y).
conclusionsPatients with nonmetastatic unilateral retinoblastoma undergoing primary enucleation can be cured with a graduated intensity approach based on pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.